达拉非尼联合曲美替尼一线治疗BRAF V600E突变转移性非小细胞肺癌:开放标签2期试验
这项2期多队列非随机开放标签研究纳入36例既往未治疗的BRAF V600E突变转移性NSCLC患者,接受达拉非尼150 mg每日两次联合曲美替尼2 mg每日一次治疗。研究者评估的确认总缓解率为64%(95% CI 46-79),其中完全缓解6%、部分缓解58%;所有患者发生至少1项任何级别不良事件,69%发生≥3级不良事件。作者认为该方案具有临床意义的抗肿瘤活性和可控的安全性。
要点
- 初治BRAF V600E突变转移性NSCLC中,达拉非尼联合曲美替尼确认总缓解率为64%(95% CI 46-79)。
- 36例中2例(6%)完全缓解,21例(58%)部分缓解;中位随访15.9个月。
- 所有患者发生任何级别不良事件,25例(69%)发生≥3级不良事件;1例致死性严重不良事件判定与治疗无关。
核心结论
- 达拉非尼联合曲美替尼在既往未治疗的BRAF V600E突变转移性NSCLC中具有临床意义的抗肿瘤活性和可控的安全性。
研究设计与样本
- 2期、序贯入组、多队列、多中心、非随机、开放标签研究,从北美、欧洲和亚洲8个国家19个中心入组 cohort C。
- 纳入≥18岁既往未治疗的转移性BRAF V600E突变NSCLC患者,接受口服达拉非尼150 mg每日两次联合口服曲美替尼2 mg每日一次直至疾病进展、不可接受的不良事件、撤回知情同意或死亡。
- 主要终点为研究者按RECIST 1.1评估的确认总缓解率;主要分析和安全性分析均按意向治疗在方案定义人群中完成。
- 2014年4月16日至2015年12月28日共36例患者入组并接受一线治疗;数据截止2017年4月28日时中位随访15.9个月(IQR 7.8-22.0)。
主要发现
- 研究者评估的确认总缓解率为23例(64%,95% CI 46-79),其中完全缓解2例(6%)、部分缓解21例(58%)。
- 所有患者发生至少1项任何级别不良事件,25例(69%)发生至少1项3级或4级不良事件。
- 发生率超过2例的3级或4级不良事件包括发热4例(11%)、丙氨酸氨基转移酶升高4例(11%)、高血压4例(11%)、呕吐3例(8%)。
- 发生率超过2例的严重不良事件包括丙氨酸氨基转移酶升高5例(14%)、发热4例(11%)、天冬氨酸氨基转移酶升高3例(8%)、射血分数下降3例(8%)。
- 报告1例判定与 study treatment 无关的致死性严重不良事件(心跳呼吸骤停)。
关键数值与推荐
- 确认总缓解率64%(95% CI 46-79),完全缓解6%,部分缓解58%。
- 3级或4级发热11%、丙氨酸氨基转移酶升高11%、高血压11%、呕吐8%。
- 严重不良事件:丙氨酸氨基转移酶升高14%、发热11%、天冬氨酸氨基转移酶升高8%、射血分数下降8%。
临床怎么用
- 作者认为达拉非尼联合曲美替尼是既往未治疗BRAF V600E突变转移性NSCLC的一种新治疗选择,具有临床意义的抗肿瘤活性和可控的安全性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: BRAFV600E mutation occurs in 1-2% of lung adenocarcinomas and acts as an oncogenic driver. Dabrafenib, alone or combined with trametinib, has shown substantial antitumour activity in patients with previously treated BRAFV600E-mutant metastatic non-small-cell lung cancer (NSCLC). We aimed to assess the activity and safety of dabrafenib plus trametinib treatment in previously untreated patients with BRAFV600E-mutant metastatic NSCLC. METHODS: In this phase 2, sequentially enrolled, multicohort, multicentre, non-randomised, open-label study, adults (≥18 years of age) with previously untreated metastatic BRAFV600E-mutant NSCLC were enrolled into cohort C from 19 centres in eight countries within North America, Europe, and Asia. Patients received oral dabrafenib 150 mg twice per day plus oral trametinib 2 mg once per day until disease progression, unacceptable adverse events, consent withdrawal, or death. The primary endpoint was investigator-assessed overall response, defined as the percentage of patients who achieved a confirmed complete response or partial response per Response Evaluation Criteria In Solid Tumors version 1.1. The primary and safety analyses were by intention to treat in the protocol-defined population (previously untreated patients). The study is ongoing, but no longer recruiting patients. This trial is registered with ClinicalTrials.gov, number NCT01336634. FINDINGS: Between April 16, 2014, and Dec 28, 2015, 36 patients were enrolled and treated with first-line dabrafenib plus trametinib. Median follow-up was 15·9 months (IQR 7·8-22·0) at the data cutoff (April 28, 2017). The proportion of patients with investigator-assessed confirmed overall response was 23 (64%, 95% CI 46-79), with two (6%) patients achieving a complete response and 21 (58%) a partial response. All patients had one or more adverse event of any grade, and 25 (69%) had one or more grade 3 or 4 event. The most common (occurring in more than two patients) grade 3 or 4 adverse events were pyrexia (four [11%]), alanine aminotransferase increase (four [11%]), hypertension (four [11%]), and vomiting (three [8%]). Serious adverse events occurring in more than two patients included alanine aminotransferase increase (five [14%]), pyrexia (four [11%]), aspartate aminotransferase increase (three [8%]), and ejection fraction decrease (three [8%]). One fatal serious adverse event deemed unrelated to study treatment was reported (cardiorespiratory arrest). INTERPRETATION: Dabrafenib plus trametinib represents a new therapy with clinically meaningful antitumour activity and a manageable safety profile in patients with previously untreated BRAFV600E-mutant NSCLC. FUNDING: Novartis.
引用
- Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017. PMID: 28919011. doi:10.1016/S1470-2045(17)30679-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。